Absolutely. Given "warp speed" here and limited opportunity for evaluation of delayed outcomes, the VAERS will be critical (https://vaers.hhs.gov/ ). 99.9% of submissions will be non-sequitur or mild but still need to be reviewed carefully given scale/speed planned here.
Post-market #COVID19 #vaccine safety surveillance is critical, as an undetected problem with the first vaccine is going to reduce trust in subsequent vaccines. - interviewed by @sudecker1 and @valeriereports at Bloomberg News.
https://www.bloomberg.com/amp/news/articles/2020-08-14/virus-vaccine-rush-leaves-little-recourse-for-anyone-it-harms …
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.